LONN Lonza Group AG

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand

Lonza Group AG / Key word(s): Personnel
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand

01.07.2024 / 07:00 CET/CEST


  • Wolfgang Wienand commences his tenure as Chief Executive Officer of Lonza Group
  • Albert M. Baehny will retire from Lonza Group following a transition period

Basel, Switzerland, 1 July 2024 – Wolfgang Wienand joins Lonza Group today as Chief Executive Officer (CEO). Wolfgang succeeds Albert M. Baehny, who took on the role of CEO ad interim in October 2023 and was Chairman of the Board of Directors of Lonza from 2018 to May 2024. Albert will work with Wolfgang to ensure a smooth leadership handover before he retires from Lonza this summer.

Jean-Marc Huët, Chairman of the Board of Directors, Lonza, commented: “On behalf of the Board, I extend a warm welcome to Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of CDMO experience, combined with deep strategic and scientific expertise. As Wolfgang joins, we look forward to an era of stable and structured growth under his leadership.”

Wolfgang Wienand, Chief Executive Officer, Lonza, commented: “Having worked in the CDMO industry for almost two decades, I always had great respect for Lonza’s ability to transform and grow at pace. It is a privilege to join this remarkable company as CEO. As I commence my journey with Lonza, we are embarking on a quest to meet and exceed the needs of our customers and their patients. I am greatly looking forward to working with the team to build on our strong foundations and create a strategy for us to deliver continued growth and reach our full potential.”

Since 2019, Wolfgang has held the role of CEO at Swiss CDMO, Siegfried. Wolfgang previously served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Prior to joining Siegfried in 2010, Wolfgang held a series of positions with increasing seniority at the German specialty chemicals company Evonik Industries.

About Lonza

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 6.7 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2023. Find out more at

Follow @Lonza on
Follow @LonzaGroup on

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd

Tel

Daniel Buchta
Investor Relations
Lonza Group Ltd
Tel

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes.

Privacy Policy



End of Media Release


Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone:
Internet:
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1935935

 
End of News EQS News Service

1935935  01.07.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1935935&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
01/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lonza Group AG

 PRESS RELEASE

Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufa...

Lonza Group AG / Key word(s): Expansion Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites 12.11.2024 / 07:00 CET/CEST The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of manufacturing space will include two additional production suites and supporting infrastructure A significant increase in bioconjugation capacity will enable Lonza to offer expertise to a broad customer base and address the expected increase in approvals Basel, S...

 PRESS RELEASE

Lonza Extends Collaboration with Major Pharmaceutical Partner for Inte...

Lonza Group AG / Key word(s): Partnership/Agreement Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates 22.10.2024 / 07:00 CET/CEST Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The extended relationship builds on a successful long-term collaboration and strong track record of manufacturing all key elements of bioconjugates at commercial scale Basel, Switzerland, 22 October 2024 – Lonza, a gl...

 PRESS RELEASE

Lonza Nominates David Meline as Independent Board Member

Lonza Group AG / Key word(s): Personnel Lonza Nominates David Meline as Independent Board Member 03.10.2024 / 09:00 CET/CEST David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual General Meeting Basel, Switzerland, 3 October 2024 - Today, Lonza’s Board of Directors announced the nomination of David Meline as an Independent Member of the Board. The Board will propose the election of David to shareholders at the Lonza Group Annual General Meeting (AGM) in May 20...

 PRESS RELEASE

Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville...

Lonza Group AG / Key word(s): Acquisition Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche 01.10.2024 / 16:45 CET/CEST The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network Additional large-scale capacity enables Lonza to harness sustained demand for commercial manufacturing, and to continue supporting a strong pipeline of molecules on the path to market B...

 PRESS RELEASE

Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASG...

Lonza Group AG / Key word(s): Partnership Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) 24.09.2024 / 14:00 CET/CEST Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply CASGEVY® will be manufactured at Lonza’s Geleen (NL) cell therapy manufacturing facility with plans to expand to Portsmouth, NH (US) Geleen (NL) site is now approved by the FDA, EMA and MHRA for the commercial production of CASGEVY® Basel, Switzerland, 24 September 2024 – Lonza, a global manufac...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch